{"entity":{"id":"nct07819604","kind":"trial","name":"Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer","aka":[],"tldr":"A phase 2 trial of serplulimab, cAPOX (capecitabine, oxaliplatin) and bevacizumab (glioblastoma use) in colorectal cancer, run by Xijing Hospital, not yet recruiting.","summary":"Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer is a phase 2, interventional study registered as NCT07819604 by Xijing Hospital, with a registry enrolment figure of 85 participants, started 2026-09-01 and due to reach its primary completion in 2027-09-01. Interventions recorded: Serplulimab; CAPOX; Bevacizumab. Conditions listed: Locally Advanced Colorectal Cancer. Primary outcome: Pathological Complete Response (pCR) Rate. Colorectal eligibility wording from the registry: \"* Histologically or pathologically confirmed locally advanced rectal adenocarcinoma, cT3/cT4N+M0 stage per AJCC/UICC 8th edition, with distance from anal verge ≤10 cm\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07819604","url":"https://clinicaltrials.gov/study/NCT07819604"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["serplulimab","capox","bevacizumab-glioma"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07819604","phase":"2","setting":"A Single-Arm, Phase II, Multicenter Study of Serplulimab Combined With CAPOX Plus Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer","sponsor":"Xijing Hospital","participation":[{"nct":"NCT07819604","source":"https://clinicaltrials.gov/study/NCT07819604","fetchedAt":"2026-10-07T16:56:52.065Z","studySha256":"9bd6281ebecdf4f581943077c73603fc51a8806bfcee467e1a8b58364607b249","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2026-09-15","leadSponsor":"Xijing Hospital","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"80 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":85,"enrolmentType":"ESTIMATED","siteCount":0,"recruitingSiteCount":0}],"started":"2026-09-01","startedType":"estimated","enrolled":85,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07819604/","neighbours":{"cancer":[{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"serplulimab","kind":"drug","name":"Serplulimab","route":"/drugs/serplulimab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}